-
Something wrong with this record ?
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
M. Maffezzoli, M. Santoni, G. Mazzaschi, S. Rodella, E. Lai, M. Maruzzo, U. Basso, D. Bimbatti, R. Iacovelli, A. Anghelone, O. Fiala, SE. Rebuzzi, G. Fornarini, C. Lolli, F. Massari, M. Rosellini, V. Mollica, C. Nasso, A. Acunzo, EM. Silini, F....
Language English Country Netherlands
Document type Observational Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1998-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1998-01-01 to 1 year ago
- MeSH
- Progression-Free Survival MeSH
- Immunotherapy MeSH
- Carcinoma, Renal Cell * secondary MeSH
- Humans MeSH
- Kidney Neoplasms * pathology MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients' counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47-0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95% CI 0.39-0.92; p < 0.001 for both]. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.
Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Diagnostic and Public Health Section of Pathology University of Verona Verona Italy
Department of Internal Medicine and Medical Specialties University of Genova Genoa Italy
Department of Medicine and Surgery Section of Radiology University of Parma Parma Italy
Department of Medicine and Surgery University of Parma Parma Italy
Department of Oncology Oncology Unit Istituto Oncologico Veneto IOV IRCCS Padua Italy
Department of Oncology Portsmouth Hospitals University NHS Trust Portsmouth UK
Medical Oncology Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Bologna Italy
Medical Oncology Ospedale Santa Corona 17027 Pietra Ligure Italy
Medical Oncology Unit 1 IRCCS Ospedale Policlinico San Martino Genoa Italy
Medical Oncology Unit Ospedale San Paolo Savona Italy
Medical Oncology Unit University Hospital of Parma Via Gramsci 14 43126 Parma Italy
Oncology Unit Macerata Hospital 62100 Macerata Italy
Pathology Unit University Hospital of Parma Parma Italy
Section of biostatistics Department of Health Sciences University of Genova Genoa Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006548
- 003
- CZ-PrNML
- 005
- 20240423155339.0
- 007
- ta
- 008
- 240412s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10585-024-10266-6 $2 doi
- 035 __
- $a (PubMed)38363410
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Maffezzoli, Michele $u Department of Medicine and Surgery, University of Parma, Parma, Italy. michele.maffezzoli@unipr.it $u Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy. michele.maffezzoli@unipr.it $1 https://orcid.org/0000000178778988
- 245 10
- $a External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations / $c M. Maffezzoli, M. Santoni, G. Mazzaschi, S. Rodella, E. Lai, M. Maruzzo, U. Basso, D. Bimbatti, R. Iacovelli, A. Anghelone, O. Fiala, SE. Rebuzzi, G. Fornarini, C. Lolli, F. Massari, M. Rosellini, V. Mollica, C. Nasso, A. Acunzo, EM. Silini, F. Quaini, M. De Filippo, M. Brunelli, GL. Banna, P. Rescigno, A. Signori, S. Buti
- 520 9_
- $a Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) had significantly improved outcomes of patients with mRCC. Predictive and prognostic factors are crucial to improve patients' counseling and management. The present study aimed to externally validate the prognostic value of a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) and red cell distribution width (RDW), in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). We performed a sub-analysis of a multicentre retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Uni- and multivariable Cox regression models were used to assess the correlation between the red cell-based score and progression-free survival (PFS), and overall survival (OS). Logistic regression were used to estimate the correlation between the score and the objective response rate (ORR). The prognostic impact of the red cell-based score on PFS and OS was confirmed in the whole population regardless of the immunotherapy combination used [median PFS (mPFS): 17.4 vs 8.2 months, HR 0.66, 95% CI 0.47-0.94; median OS (mOS): 42.0 vs 17.3 months, HR 0.60, 95% CI 0.39-0.92; p < 0.001 for both]. We validated the prognostic significance of the red cell-based score in patients with mRCC treated with first-line immunotherapy combinations. The score is easy to use in daily clinical practice and it might improve patient counselling.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x sekundární $7 D002292
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, 62100, Macerata, Italy
- 700 1_
- $a Mazzaschi, Giulia $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy
- 700 1_
- $a Rodella, Sara $u Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Lai, Eleonora $u Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Maruzzo, Marco $u Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Basso, Umberto $u Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Bimbatti, Davide $u Department of Oncology, Oncology Unit, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
- 700 1_
- $a Iacovelli, Roberto $u Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Anghelone, Annunziato $u Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Rebuzzi, Sara Elena $u Medical Oncology Unit, Ospedale San Paolo, Savona, Italy $u Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genoa, Italy
- 700 1_
- $a Fornarini, Giuseppe $u Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Lolli, Cristian $u Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
- 700 1_
- $a Rosellini, Matteo $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy
- 700 1_
- $a Nasso, Cecilia $u Medical Oncology, Ospedale Santa Corona, 17027, Pietra Ligure, Italy
- 700 1_
- $a Acunzo, Alessandro $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy
- 700 1_
- $a Silini, Enrico Maria $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Pathology Unit, University Hospital of Parma, Parma, Italy
- 700 1_
- $a Quaini, Federico $u Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a De Filippo, Massimo $u Department of Medicine and Surgery, Section of Radiology, University of Parma, Parma, Italy
- 700 1_
- $a Brunelli, Matteo $u Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy
- 700 1_
- $a Banna, Giuseppe L $u Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK $u Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK
- 700 1_
- $a Rescigno, Pasquale $u Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK
- 700 1_
- $a Signori, Alessio $u Section of biostatistics, Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy
- 700 1_
- $a Buti, Sebastiano $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43126, Parma, Italy
- 773 0_
- $w MED00007574 $t Clinical & experimental metastasis $x 1573-7276 $g Roč. 41, č. 2 (2024), s. 117-129
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38363410 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155335 $b ABA008
- 999 __
- $a ok $b bmc $g 2080878 $s 1216315
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 41 $c 2 $d 117-129 $e 20240216 $i 1573-7276 $m Clinical & experimental metastasis $n Clin Exp Metastasis $x MED00007574
- LZP __
- $a Pubmed-20240412
